Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

Objective: To obtain results of the second year extension of an original 3 month randomised, placebo controlled trial (and the 1 year extension study) assessing the use of infliximab, a monoclonal antibody to tumour necrosis factor α, for the treatment of patients with ankylosing spondylitis (AS). M...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Braun, J, Brandt, J, Listing, J, Zink, A, Alten, R, Burmester, G, Gromnica-Ihle, E, Kellner, H, Schneider, M, Sorensen, H, Zeidler, H, Sieper, J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2005
Konular:
Extended Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1755337/
https://ncbi.nlm.nih.gov/pubmed/15388511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2004.025130
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller